Business Context and Reporting Period
Company: Bionexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2023
Reporting Status: Non-accelerated filer, Smaller reporting company, Emerging growth company.
Operations: The Company operates through two Malaysian subsidiaries: MRNA Scientific Sdn. Bhd. (molecular lab for disease/cancer detection) and Chemrex Corporation Sdn. Bhd. (industrial chemical wholesaler). Chemrex accounts for approximately 99.6% of total revenue.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2023 | Dec 31, 2022 (Balance Sheet) |
|---|---|---|---|
| Revenue | $2,553,686 | $7,497,739 | - |
| Gross Profit | $354,332 | $1,062,943 | - |
| Gross Margin | 13.9% | 14.2% | - |
| Net Loss | $(2,608,143) | $(2,936,460) | - |
| Operating Cash Flow | - | $(1,039,686) | - |
| Cash & Equivalents | - | $6,146,883 | $2,118,864 |
| Total Assets | - | $11,465,522 | $8,740,162 |
| Total Liabilities | - | $1,777,807 | $2,075,149 |
| Working Capital | - | $6,625,767 | $4,017,749 |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenue decreased 7.3% to $7.5M compared to $8.1M in the prior year. This was driven by a 7.2% drop in Chemrex sales due to market competition and lack of new projects, and a 27.8% drop in MRNA Scientific revenue due to reduced patient visits post-pandemic.
- Significant Net Loss: Net loss for the nine months ended Sep 30, 2023, was $2.94M, a substantial increase from the $199K loss in the same period in 2022.
- Operating Expense Surge: Operating expenses increased 256.4% year-over-year to $4.43M. This spike is primarily attributed to one-time costs associated with the Nasdaq listing (underwriting fees, legal, audit, and listing expenses) and a $1.37M provision for expected credit losses on trade receivables.
- Liquidity Improvement: Cash and cash equivalents increased from $2.12M to $6.15M, driven by $5.75M in gross proceeds from a public offering in July 2023.
- Stock Structure: The Company effected a 12-for-1 reverse stock split in July 2023. As of November 20, 2023, 17,667,663 shares were outstanding.
Guidance, Outlook, Risks, and Unusual Items
- Capital Raise: In July 2023, the Company completed a public offering of 1,437,500 shares at $4.00/share, raising $5.75M gross ($5.29M net). Warrants for 115,000 shares were issued to the underwriter.
- Management Turnover: Significant executive changes occurred subsequent to the period end:
- COO Liong Tai Tan resigned (effective Aug 31, 2023); replaced by Lee Su-Leng Tan.
- CEO Sook Keng Yeoh resigned (effective Oct 4, 2023); replaced by Chi Yuen Leong.
- CFO Wei Li Leong resigned (effective Oct 30, 2023); a replacement is being sought.
- Unusual Items:
- Provision for Credit Losses: A $1.37M allowance for expected credit losses was recorded in Q3 2023, significantly impacting operating income.
- Share Issuance Discrepancy: The Company noted a potential discrepancy regarding 1,039,926 shares issued to Cede & Co. during the reverse stock split round-up. An amendment to the 10-Q may be filed if the discrepancy is confirmed.
- Risks: The Company faces risks related to foreign currency translation (MYR to USD), reliance on a single major subsidiary (Chemrex), and the high cost of maintaining public company status. Management believes current cash reserves are sufficient for at least 12 months of operations.
Investor Verification Checklist
- Share Count Accuracy: Verify the resolution of the 1,039,926 share issuance discrepancy mentioned in Item 5 regarding the reverse stock split round-up.
- Receivables Quality: Review the specific customers included in the $1.37M allowance for expected credit losses and the likelihood of recovery.
- Executive Continuity: Monitor the appointment of a permanent CFO and the stability of the new management team following multiple resignations.
- Chemrex Dependency: Assess the sustainability of Chemrex's revenue given the cited market competition and lack of new projects.
- Listing Costs: Confirm that the significant operating expenses incurred in 2023 were primarily one-time listing costs and not indicative of a permanent increase in the cost structure.